Table 1.
Demographic and Clinical Characteristics of Study Participants
| Characteristics | Overall | Incident SISV statusa |
||
|---|---|---|---|---|
| Yes | No | p-value | ||
| Study participation and follow-up | ||||
| Donors, n | 13,930 | 221 | 13,709 | |
| Donations, nb | ||||
| Total | 39,736 | 796 | 38,940 | |
| Per participant | ||||
| Median (IQR) | 2 (2–3) | 3 (2–4) | 2 (2–3) | |
| Minimum | 2 | 2 | 2 | |
| Maximum | 19 | 19 | 18 | |
| Time at risk (person-days) | 1,127,071 | 19,575 | 1,107,496 | |
| Demographic characteristics | ||||
| Age, years, median (IQR) | 59 (43–68) | 52 (40–63) | 59 (43–68) | <0.01c |
| Male, n (%) | 7,012 (50.3%) | 132 (59.7%) | 6,880 (50.2%) | <0.01d |
| Female, n (%) | 6,918 (49.7%) | 89 (40.3%) | 6,829 (49.8%) | |
| Race–ethnicity, n (%) | ||||
| White, non-Hispanic | 10,057 (72.2%) | 167 (75.6%) | 9,890 (72.1%) | 0.03d |
| Hispanic | 2,320 (16.7%) | 44 (19.9%) | 2,276 (16.6%) | |
| Asian, non-Hispanic | 940 (6.8%) | 4 (1.8%) | 936 (6.8%) | |
| Black, non-Hispanic | 299 (2.2%) | 3 (1.4%) | 296 (2.2%) | |
| Other | 314 (2.3%) | 3 (1.4%) | 311 (2.3%) | |
| Cardiometabolic indicators at baseline | ||||
| Total cholesterol, n (%) | ||||
| Normal: ≤200 mg/dL | 9,592 (68.9%) | 153 (69.2%) | 9,439 (68.9%) | 0.86d |
| Borderline high: >200 to ≤239 mg/dL | 3,358 (24.1%) | 50 (22.6%) | 3,308 (24.1%) | |
| High: ≥240 mg/dL | 980 (7.0%) | 18 (8.1%) | 962 (7.0%) | |
| Blood pressure | ||||
| Systolic, mmHg, median (IQR) | 126 (116–138) | 128 (121–139) | 126 (116–138) | 0.03c |
| Diastolic, mmHg, median (IQR) | 76 (70–83) | 78 (72–84) | 76 (70–83) | <0.01c |
| Normotension, n (%) | 6,716 (48.2%) | 88 (39.8%) | 6,628 (48.4%) | 0.01d |
| Hypertension, n (%) | 7,214 (51.8%) | 133 (60.2%) | 7,081 (51.7%) | |
| BMI categories, n (%) | ||||
| Underweight: <18.5 kg/m2 | 33 (0.2%) | 0 (0.0%) | 33 (0.2%) | <0.01e |
| Normal: ≥18.5 and <25.0 kg/m2 | 3,866 (27.8%) | 38 (17.2%) | 3,828 (27.9%) | |
| Overweight: ≥25.0 and <30.0 kg/m2 | 5,317 (38.2%) | 103 (46.6%) | 5,214 (38.0%) | |
| Obesity: ≥30.0 kg/m2 | 4,714 (33.8%) | 80 (36.2%) | 4,634 (33.8%) | |
Among donors without seropositivity at baseline (first visit contributed to study), incidence was defined as the number of newly observed cases (anti-N seropositivity) during the follow-up period. At-risk time (person-days) was defined as the last visit to the first visit among participants without SISV or an interval (visit of incident SISV detection to visit immediately preceding incident SISV) among participants with SISV.
In this table, all values reflect the baseline study visit of each donor. The exceptions were the number of donations (total among all donors; median, minimum, maximum per donor).
Variable was not normally distributed on the basis of the Kolmogorov–Smirnov test statistic (p<0.05). p-value was calculated from the Kruskal–Wallis test statistic.
p-value was calculated from the Mantel–Haenszel chi-square test statistic.
p-value was calculated from Fisher's exact test statistic.
anti-N, antibodies specific to SARS-CoV-2 nucleocapsid protein antibodies; SISV, SARS-CoV-2 infection among those with serologic evidence of vaccination.